PART Ⅱ: Role Of Human Primary Renal Fibroblast in TGF-β1-Mediated Fibrosis-Mimicking Devices

Mar 26, 2022


Contact: Audrey Hu Whatsapp/hp: 0086 13880143964 Email: audrey.hu@wecistanche.com


PART Ⅱ: Role of Human Primary Renal Fibroblast in TGF-β1-Mediated Fibrosis-Mimicking Devices

Seong-Hye Hwang, Yun-Mi Lee & et al.

Abstract

Renal fibrosis is a progressive chronic kidney disease that ultimately leads to end-stage renal failure. Despite several approaches to combat renal fibrosis, an experimental model to evaluate currently available drugs is not ideal. We developed b-mimicking models using three-dimensional (3D)co-culture devices designed with three separate layers of tubule interstitium, namely, epithelial, fibroblastic, and endothelial layers. We introduced human renal proximal tubular epithelial cells (HK-2), human umbilical vein endothelial cells, and patient-derived renal fibroblasts, and evaluated the effects of transforming growth factor-β (TGF-β)and TGF-β inhibitor treatment on this renal fibrosis model. The expression of the fibrosis marker alpha-smooth muscle actin upon TGF-β1 treatment was augmented in monolayer-cultured HK-2 cells in a 3D disease model. In the vascular compartment of renal fibrosis models, the density of vessels was increased and decreased in the TGF-β-treated group and TGF-β-inhibitor treatment group, respectively. Multiplex ELISA using supernatants in the TGF-β-stimulating 3D models showed that pro-inflammatory cytokine and growth factor levels including interleukin-1 beta, tumor necrosis factor-alpha, basic fibroblast growth factor, and TGF-β1, TGF-β2, and TGF-β3 were increased, which mimicked the fibrotic microenvironments of human kidneys. This study may enable the construction of a human renal fibrosis-mimicking device model beyond traditional culture experiments.

Keywords: renal fibroblast; fibrosis; TGF-β1

cistanche tubolosa health benefits: treating chronic kidney diseases

cistanche tubolosa health benefits: treating chronic kidney diseases


CLICK HERE TO PART Ⅰ

3. Discussion

TGF-β1 plays an important role in matrix accumulation in renal fibrogenesis and inhibits proliferation in most cells, including glomerular epithelial and endothelial cells, as well as tubular epithelial cells 【1】. However, TGF-ß1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2) [8].

In the present study, we established a fibrosis-mimicking device using three essential cellular components, including human primary renal fibroblasts, renal tubular epithelial cells, and human endothelial cells and evaluated it as a renal fibrosis model based on TGF-β1 stimulation. To generate renal fibrosis-on-a-chip, we established a novel 3D-culture system designed with three separate parts of tissue, aiming to overcome obstacles associated with renal disease modeling. Our study demonstrated that TGF-β1 induced cellular responses, including tubular epithelial-mesenchymal transition (EMT)of epithelial cells, microvascular alteration of endothelial cells, and cytokine changes in renal fibroblasts. This is the first study to introduce a fibrosis-mimicking device comprising primary fibroblasts derived from human kidneys and stimulated fibroblasts isolated from patients with TGF-β1, a known inducer of fibrotic responses generally used as the standard to mimic fibrosis in cell cultures [9]. These results suggest that TGF-β1-treated epithelial cells are converted to a mesenchymal cell-like phenotype. When TGF-β1 is administered to fibroblasts, various cytokines are altered to reflect the induction of fibrotic processes. It is apparent that in the renal fibrosis model, fibroblasts are the main force behind the development of the established culture system through TGF stimulation.

Davis et al, reported that the 3Dculture of endothelial cells is sufficient for the cells to invade and form a lumen and tube network, following an intact organism in vivo [10,11]. Several groups have reported that 3D-culture models exhibit higher levels of nephrotoxicity than 2D cell-culture models [12]. Furthermore, the expression of nephrotoxicity-and inflammation-related genes was significantly higher in the renal 3D cell-culture model than in a typical2D culture[13].

In this study, the culture media of human renal fibrosis-on-a-chip had a significantly higher level of cytokines compared to that in 2Dculture. Our group has shown that patient-derived fibroblasts can recreate native renal tissues, including endothelial and epithelial cell layers, through our suggested fibrosis-on-a-chip model. Consequently, these findings indicate that the renal fibrosis-on-a-chip model accurately simulates the microphysical environment of the human kidney. In addition, because the fibroblasts cultured in the chip are derived from patients, other clinically relevant patient models can be easily and clearly obtained in a safe manner. Therefore, the human renal fibrosis-on-a-chip model system can allow for the development of personalized medicine with sensitive measurements of epithelial and endothelial functions. In our experiments, fibrosis and angiogenesis were decreased in the TGF-β inhibitor-treated groups. TGF-β inhibitors are natural antagonists of TGF-β, which have been demonstrated using various renal disease models. It appears that it is possible to conduct experiments to confirm the effectiveness of treatment in disease models using therapeutic agents such as this TGF-β inhibitor. Therefore, this chip has provided a means to develop an improved model of renal fibrosis to measure cell morphology and function and might be useful in performing nephrotoxicity assessments for pharmaceuticals.

TGF-β is the predominant profibrotic factor in various kidney diseases [14] and plays a role in angiogenesis [15]. The angiogenic effects of TGF-β are very complex and can have either proangiogenic or antiangiogenic activity depending on the setting and various regulatory factors [16]. Angiogenic growth factors such as VEGF and FGF-2induce angiogenesis in vivo appear to play a central role in the modulation of angiogenesis in vivo [17-20]. Some evidence indicates that these two factors can act synergistically to promote endothelial cell morphogenetic events [21,22]. We have provided evidence that VEGF mRNA expression and FGF-2 protein secretion are significantly elevated by TGF-β1 in 3D chips compared to 2D culture.

The limitation of our fibrosis models might be that they were created in a relatively short time period, 24 h. TGF-beta has pro-fibrotic and anti-inflammatory properties within an early fibrosis process, not in the chronic process. Conventionally, TGF-β has been primarily utilized in cytokine-induced fibrosis models. However, since only one cytokine cannot be represented in vivo, fibrosis induction models using several additional candidate substances such as TGF-β and BMP7 have been proposed. However, two or three cytokines are still not sufficient to reproduce in vivo. We used TGF-β as the starting point; however, we tried to implement an in vivo microenvironment on the chip by inducing a more diverse cytokine storm. Fibroblast, a major cellular component of fibrosis, was introduced, and secondary stimulation of more diverse cytokines (IL-1β, TNF-α, b-FGF, TGF-β1, TGF-β2, and TGF-β3) was induced in fibroblasts stimulated with TGF-β. Thus, an environment similar to fibrosis in the human body was reproduced.

cistanche deserticola extract: treating kidney diseases

cistanche deserticola extract: treating kidney diseases

4. Materials and Methods

4.1.Cell Cultures

Kidney fibroblasts(KFs)were isolated from biopsies of the normal tissue portion of renal cell carcinoma patients with an estimated glomerular filtration rate (eGFR)>60 mL/minute/1.73 m2 after patients had given their consent to a second biopsy for research purposes. KFs were cultured in a fibroblast growth medium (FGM-2, Lonza, Switzerland), and passages 3 to 4 were used for the experiments. Renal fibroblasts were scraped from the culture for 1-2 weeks until the cells formed a monolayer. To eliminate epithelial cells contaminating the culture, fibroblasts were selected using magnetic anti-fibroblast beads (Miltenyi Biotec Inc., Auburn, CA, USA)after the first passage. Cells were detached using 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA)(Welgene, Gyeongsan, Korea), incubated with anti-fibroblast beads, and separated using a magnetic column, and the flow-through was collected. The purified primary fibroblasts were characterized by fluorescence-activated cell-sorting (FACS) analysis using PE-conjugated anti-fibroblast antibodies. The gentle magnetic-activated cell sorting (MACS)Dissociator was used for gentle kidney tissue mincing. An Octo MACSTM Magnetic Separator with MACS LS columns (with plungers) applied for the purification of microbead-labeled cells was purchased from Miltenyi Biotec Inc. (Auburn, CA, USA). Gentle MACS C tubes (Miltenyi Biotec Inc., Auburn, CA, USA)were used for kidney mincing for cell separation. MACS Smart Strainers (70 um)were obtained from Miltenyi Biotec Inc. (Auburn, CA, USA). Column buffer was used to wash columns and resuspend cell pellets. The buffer was prepared as a solution containing 0.5 %bovine serum albumin (BSA) with 2 mM EDTA in phosphate-buffered saline (PBS) (pH7.4) and purchased from Miltenyi Biotec Inc. (Auburn, CA, USA). Green fluorescent protein-expressing human umbilical-vein endothelial cells(GFP-HUVECs, Lonza, Switzerland) were cultured in Endothelial Growth Medium (EGM-2, Lonza, Switzerland), and cells in passages 3 to 4 were used. Human proximal tubular cell line (human kidney-2(HK-2) cells were obtained from the American Type Culture Collection(ATCC). The cell line was grown in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 ug/mL). Reagents were purchased from Gibco (Rockville, MD, USA). All cells were detached using 0.05% Trypsin-EDTA and maintained in a humidified incubator at 37 °C and 5% CO2. KFs were re-suspended in FGM-2 at a cell concentration of 4×10° cells/mL. Human kidney tubular epithelial cells (HK-2) were re-suspended at a concentration of 2×10° cells/mL in high-glucose DMEM.GFP-HUVECs were resuspended at a concentration of 2×10° cells/mL in EGM-2.

4.2.Reagents

The matrix was composed of fibrin gels, including commercially available fibrinogen from bovine plasma, aprotinin from bovine lung, and thrombin from bovine plasma. The aforementioned three materials were purchased from Sigma (St. Louis, MO, USA). Fibrinogen was dissolved in l×PBS in a water bath (37°C) for 30 min at a concentration of 10 mg/mL. Thrombin and aprotinin were dissolved in deionized water at a concentration of 50 units/mL and 4 TIU/mL. The three solutions were sterilized by filtering through a 0.22 μm filter. Recombinant human TGF-β1 was obtained from PeproTech EC Ltd. (London, UK). A specific inhibitor of TGF-beta receptor kinase, SB431542, was purchased from Tocris Cookson, Inc. (Ellisville, MO, USA).

4.3. Cell Patterning in the Device

Before cell seeding to facilitate tight bonding, the device was treated for 1 min in a plasma machine (Femto Science Inc., Suwon, Korea) with a power of 70 W, 50 Hz. Plasma treatment-induced surface hydrophilicity and helped facilitate gel patterning and media loading. To avoid changes in hydrophilicity, experiments were performed within 30 min after plasma treatment. Different cellular patterning within the devices can be done in a highly customizable fashion. It was important to determine the composition and concentration of the different cell types to be patterned beforehand. For cellular hydrogel suspensions, 37.5 μL of cell suspension and a separated aliquot of 12.5 μL of 10 mg/mL fibrinogen solution (250 μL of 10 mg/mL fibrinogen solution with 40 μL of 4 TIU/mL aprotinin) were prepared to be mixed immediately prior to loading. Immediately prior to loading, the 37.5 μL of cell suspension was mixed with 12.5 μL of 10 mg/mL fibrinogen until homogenized. The 50uL of hydrogel was mixed with a 1 uL droplet of thrombin (0.5 unit/mL). Immediately after mixing, thrombin with a fibrin suspension of GFP-HUVECs (cell concentration of 2×10' cells/mL) was injected into the outer edge of the outer channel (Figure 3, Gel A). We waited 3 min for fibrinogen crosslinking to be complete. Immediately after mixing, thrombin with a fibrin suspension of KFs(cell concentration of 4×10° cells/mL) was placed on each side of the reservoir floor per well (Figure 3, Gel C). This fibrin suspension of KFs was allowed to crosslink at room temperature for 3 min. A cell suspension of 10 μL human renal proximal tubular epithelial cells(HK-2) was injected into the injection port of the inner channel (Figure3, Gel B).To attach HK-2 to the wall of the fibrin gel in the GFP-HUVECs channel, the device was turned 90 degrees and placed in the 5% CO, an incubator for 30 min at 37 °C. The HK-2 settled down and formed a cell sheet on the side of the fibrin gel.

After attaching the HK-2, the device was filled with EGM-2. The device was incubated for 3 days at 37°C in a 5% CO, incubator. The medium was changed with or without 5ng/mL TGF-β1 and with5ng/mL TGF-β1 and 10 um TGF-β1 inhibitor after three days of incubation (Figure 3).

what is cistanche

what is cistanche

4.4. Imunocytofluorescence

Co-cultured tissues in the device were fixed with 4%(w/v) paraformaldehyde solution (Biosesang, Seongnam, Korea) in PBS(Welgene, Gyeongsan, Korea) for 20 min, followed by permeabilization with a 20 min immersion in 0.15%Triton X-100(Sigma, St.Louis, MO, USA). The samples were then treated with 3%BSA(Sigma, USA)for 1 h. The cells were incubated with antibodies purchased from Abcam. The primary antibodies were anti-cytokeratin 8 and anti-o-SMA, left for 2 days at room temperature (RT). Alexa Fluor 647 conjugated donkey anti-rabbit IgG(H+L) was used as the secondary antibody. DNA labeling was performed with a 1:250 dilution of Hoechst33342(Thermo Scientific, Rockford, IL, USA)for 3 h at RT. Images were collected using a Zeiss LSM 710 confocal laser microscope. The mean fluorescence intensity(MFI)was measured using ImageJ and a fluorescence-intensity analyzer.

4.5. Multiplex Analysis of Cytokines

The MSD V-Plex Cytokine and Angiogenesis Panel 1 Human kit (Rockville, MD, USA)was used to measure interleukin-1 beta (IL-1ß) and basic fibroblast growth factor (b-FGF)concentrations in single samples, according to the manufacturer's instructions. All samples were assessed for total protein levels of IL-1β and b-FGF. The amount (in pg/mL) was quantified from the standard curve of each measurement.

4.6. Multiplex Bead Immunoassay

Cytokine concentrations were analyzed using a multiplex bead immunoassay system (Procarta Cytokine Assay Kit; Affymetrix, Inc., Santa Clara, CA, USA), based on multi-plexing technology(xMAP; Luminex, Austin, TX, USA), according to the manufacturer's instructions. The data were acquired using a Luminex-compatible workstation and its manager software (Bio-Plex workstation and version 6.0 software; Bio-Rad, Tokyo, Japan), according to the manufacturer's instructions. Human TGF-β1, TGF-β2, and TGF-β3 related to the fibrosis process were analyzed simultaneously in the diluted samples. The isoforms of TGF-β were detected using Bio-Plex 200 Systems and commercially available Bio-Plex ProTM Human TGF-β assays (Bio-Rad Laboratories, Inc); based on the information provided by the manufacturer. The multiplex assay kit can quantitatively measure multiple cytokines from the supernatant with a lower limit of detection of 1 pg/mL per cytokine. Each sample was run as a single measurement for a limited quantity of the collected supernatant.

4.7.Real-Time PCR

RNA extraction was performed using TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Master Mix and a Revert Aid First Strand cDNA Synthesis Kit were used for the reverse transcription of the total RNA.qPCR were performed using the Applied BiosystemsTM PowerUpTM SYBRTM Green Master Mix(Thermo Fisher Scientific, Inc.). The specific primers were prepared by Bioneer (Daejeon, Korea) and used in this experiment as follows. The primer sequences are summarized in Table 1.

Ten microliters of PowerUp SYBR Green Master Mix, 4 μL of cDNA, and 2 pmol of each primer were used for real-time PCR in a final volume of 20 μL. The reaction was carried out at 95°C for 1s and 60°C for 20 s for 45 cycles after denaturation at 95°C for 20 s. PCR was performed in duplicate or triplicate for each sample. cDNA levels were determined using a standard curve of cycle thresholds. All data for each cDNA were within the corresponding standard curve. The data obtained were normalized to β-actin cDNA.

4.8. Statistical Analysis

Quantitative data are presented as mean ±SD or SE of at least three independent experiments. Statistical analyses were performed using a two-tailed Student's t-test. We considered a significant difference only at a 95% confidence level or higher (p<0.05).


5. Conclusions

In summary, the protocols in this study enabled the construction of human renal fibrosis-mimicking devices as a model and showed various effects that are not possible in 2D-culture experiments. We believe that the evaluation strategy proposed in this study will lead to a better understanding of the detailed fibrosis mechanisms involved in pathological changes during renal disease. The developed 3D renal fibrosis-on-a-chip could be used as a potential in vitro model, which will bring us closer to creating an enhanced kidney-on-a-chip model.

cistanche phelypaes: treatment for kidney diseases

cistanche phelypaes: treatment for kidney diseases

References

1. Border, W.; Noble, N. Transforming growth factor in tissue fibrosis.N. Engl. J. Med.1994, 331,1286-1292.

2. Wang, W.;Huang, X.R.;Li,A.G.;Liu, F;Li,J.; Truong, L.D.; Wang, X.J.; Lan, H.Y.Signaling mechanism of TGF-betal in the prevention of renal inflammation: Role of Smad. I. Am. Soc. Nephrol.2005, 16, 1371-1383. [CrossRef]

3. Liu,Y. Renal fibrosis: New insights into the pathogenesis and therapeutics.Kidney Int.2006,69,213-217. [CrossRef][PubMed]

4. Andes, D.; Craig, W.A. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int. J.Antimicrob.Agents 2002, 19,261-268. [CrossRef]

5. Kim, S.; Takayama, S.Organ-on-a-chip and the kidney. Kidney Res. Clin. Pract.2015, 34, 165-169.[CrossRef][PubMed]

6. Jang, K.J.; Mehr, A.P; Hamilton, G.A.; McPartlin, L.A.; Chung, S.; Suh, K.Y; Ingber, D.E.Human kidney proximal tubule on-a-chip for drug transport and nephrotoxicity assessment. Integer. Biol. 2013,5,1119-1129. [CrossRef[PubMedl

7. Reardon, S. 'Organs-on-chips' go mainstream. Nature 2015, 523, 266. [CrossRef]

8. Strutz, F; Zeisberg, M; Renziehausen, A.; Raschke, B.; Becker, V; Kooten, C.V.; MuLler, G.A. TGF-β1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2).Kidney Int. 2001, 59, 579-592.[CrossRef][PubMed]

9. Zanotti, S.; Bragato, C.; Zucchella, A.; Maggi, L.; Mantegazza, R.; Morandi, L.; Mora, M.Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. Life Sci. 2016, 145,127-136. [CrossRef]

10. Davis, GE.:Camarillo. C, W. An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in a three-dimensional collagen matrix. Exp. Cell Res. 1996, 224, 39-51.[CrossRef]

11. Bayless, K.J.; Davis, G. The Cdc42 and Race GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J. Cell Sci. 2002,115,1123-1136. [CrossRef [PubMed]

12. DesRochers, T.M.; Suter, L.; Roth, A.; Kaplan, D.L. Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity. PLoS ONE 2013, 8, e59219. [CrossRef]

13. Astashkina, A.I.; Mann, B.K; Prestwich, G.D.; Grainger, D.W. Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines. Biomaterials 2012, 33, 4712-4721. [CrossRef] [PubMed]

14. Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-beta: The master regulator of fibrosis. Nat.Rev.Nephrol.2016,12, 325-338. [CrossRef]

15. Pardali,E.;Goumans, M.J.;ten Dijke,P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol.2010, 20, 556-567. [CrossRef] [PubMed]

16. Cunha, S.L; Pietras, K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011,117,6999-7006.[CrossRef]

17.Klagsbrun, M.;D'Amore, P.A. Regulators of angiogenesis. Annu. Rev. Physiol.1991,53, 217-239. [CrossRef]

18. Folkman, J.;Shing, Y.Angiogenesis. J.Biol. Chem.1992, 267,10931-10934. [CrossRef]

19. Shweiki, D. Itin, A.Soffer, D.Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-848. [CrossRef]

20. Kim, K.J.; Li, B.; Winer, J.; Armanini, M; Gillett, N.; Phillips, H.S.; Ferrera, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844. [CrossRefl]

21. Pepper, M.S.; Ferrara, N.; Orci, L.; Montesano, R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.Biochem. Biophys. Res. Commun.1992,189,824-831.[CrossRefl

22. Goto, F.; Goto, K.; Weindel, K.; Folkman, J.Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Investig.1993,69, 508-551.[PubMed]

CLICK HERE TO PART Ⅰ



You Might Also Like